Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility trial of Sativex for agitation and aggression in Alzheimer's dementia
2020-001056-17Phase 2Unknown
- Sponsor
- King's College London
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cannabidiol in Alzheimer's disease (AD) (2 arms), sponsored by King's College London. Primary endpoint: Feasibility outcomes. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2020-001056-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001056-17.